13/11

Highlights of China International Import Expo (CIIE) 2023 - Amoy Diagnostics Announced Multiple Collaborations with AstraZeneca and Pfizer

AmoyDx announced multiple collaborations with AstraZeneca and Pfizer during the 2023 China International Import Expo (CIIE), held on November 5-10 in Shanghai China. These partnerships aim to jointly promote the development of precision diagnostics

03/11

AmoyDx® Microsatellite Instability (MSI) Detection Kit Received NMPA Approval for Pan-Tumor Immunotherapy Companion Diagnostics

National Medical Products Administration (NMPA) granted approval to AmoyDx^® Microsatellite Instability (MSI) Detection Kit

18/09

Meet us at ESMO 2023

AmoyDx is excited to be part of this incredible gathering for oncology community.

15/08

AmoyDx Collaborates with AstraZeneca to Develop a HER2 Companion Diagnostic for Lung Cancer in China

We are thrilled to announce that AmoyDx reaches a new collaboration agreement with AstraZeneca. Under this agreement, the AmoyDx^® Essential NGS panel will be used as a companion diagnostic of ENHERTU^® to identify HER2 (ERBB2) mutations in patients with no

24/07

AmoyDx Signed a Collaboration Agreement with AstraZeneca for HRD Companion Diagnostic

Amoy Diagnostics Co., Ltd (AmoyDx), a China-based innovative molecular diagnostics company (SZSE: 300685), announced that it has entered into a Companion Diagnostic Collaboration Agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical

08/05

Meet our team at 2023 ASCO Annual Meeting in Chicago, June 2-6

Amoydx will be attending the 2023 ASCO Annual meeting held in Chicago, IL from June 2-6.